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Abstract: Aging is associated with multiple molecular and functional changes in haematopoietic
cells. Most notably, the self-renewal and differentiation potential of hematopoietic stem cells (HSCs)
are compromised, resulting in myeloid skewing, reduced output of red blood cells and decreased
generation of immune cells. These changes result in anaemia, increased susceptibility for infections and
higher prevalence of haematopoietic malignancies. In HSCs, age-associated global epigenetic changes
have been identified. These epigenetic alterations in aged HSCs can occur randomly (epigenetic drift)
or are the result of somatic mutations in genes encoding for epigenetic proteins. Mutations in loci
that encode epigenetic modifiers occur frequently in patients with haematological malignancies, but
also in healthy elderly individuals at risk to develop these. It may be possible to pharmacologically
intervene in the aberrant epigenetic program of derailed HSCs to enforce normal haematopoiesis
or treat age-related haematopoietic diseases. Over the past decade our molecular understanding
of epigenetic regulation has rapidly increased and drugs targeting epigenetic modifications are
increasingly part of treatment protocols. The reversibility of epigenetic modifications renders these
targets for novel therapeutics. In this review we provide an overview of epigenetic changes that occur
in aging HSCs and age-related malignancies and discuss related epigenetic drugs.
Keywords: aging; haematopoietic stem cells; epigenetics; therapeutic targeting; age-related
haematopoietic malignancies
1. Epigenetic Regulation of HSCs
Haematopoiesis is a tightly regulated process and involves the control of transcription of genes
that guard the balance between self-renewal of HSCs and their proper differentiation into all mature
blood cell lineages. As primitive stem cells differentiate towards functionally mature peripheral blood
cells, massive genome-wide changes in gene expression patterns occur [1]. In contrast, when HSCs
self-renew at least one of the two daughter cells is expected to inherit a gene expression pattern that is
highly similar, if not identical, to the mother stem cell. Genes involved in differentiation pathways
must be repressed in HSCs, while self-renewal genes are repressed upon differentiation. Complex
epigenetic control mechanisms play a crucial role in coordinating gene expression patterns that guard
this balance between self-renewal and differentiation. Such epigenetic modifications involve both DNA
methylation and chromatin conformation and, thus, impact the accessibility of DNA to transcription
factors and the transcriptional machinery. Posttranslational modifications of histones that affect
chromatin conformation mostly include methylation, acetylation and ubiquitination of histone tails
(Figure 1).
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Figure 1. Epigenetic modifications and their effect on DNA accessibility. 
Such epigenetic modifications can be actively deposited or removed by epigenetic enzymes. The 
role of these enzymes in haematopoiesis and leukemogenesis will be the main focus of this review. 
Passive (non-enzyme mediated) changes of epigenetic modifications also take place and are part of 
the replication process of cells. Every cell division changes in epigenetic landscape occur, most of 
which are temporary. For example, during DNA replication the newly formed strand is generated 
without the methylation marks present on the template strand, referred to as passive DNA 
methylation. In contrast to active DNA demethylation, DNA replication associated passive 
demethylation is not complete, since methylation marks on the parental strand remain. The parental 
methylation pattern on the newly formed strand is deposited by DNA methylases, such as DNMT1 
[2]. Beyond DNA methylation, the parental epigenetic histone marks also have to be established on 
the newly synthesized histones. Replication stress can disturb posttranscriptional deposition of the 
parental chromatin marks and DNA methylation state and, thus, lead to epigenetic changes [3]. 
On the other hand, new DNA methylation patterns and histone modifications are actively 
deposited or removed by dedicated enzymes, or recognized by specific readers. Importantly, a large 
body of evidence has demonstrated an important, if not essential, role for many of these epigenetic 
writers, readers, and erasers in normal haematopoiesis. Multiple epigenetic proteins have been 
associated to control self-renewal capacity of HSCs. Table 1 provides an overview of the most 
prominent of such epigenetic haematopoietic stem cell genes.  
Table 1. Overview of major epigenetic writers, readers and erasers that play a role in HSC self-
renewal. 
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novo DNA methylation. 
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potential. TET2 deletion resulted in enhanced 
HSC self-renewal and enhanced myelopoiesis. 
TET2 mutations are mutually exclusive with gain 
of function mutations IDH1/2 in AML. 
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IDH1 mutations impair histone demethylation and result in
hypermethylation. TET2 function becomes disrupted and
differentiation is inhibited. Mutant IDH1/2 overexpression in
primary bone marrow cells disturbs haematopoietic
differentiation and leads to elevated numbers of HSPCs.
[18–20]
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Crucial for embryonic erythropoiesis. Not essential for adult
haematopoiesis. [25–28]
MLL proteins H3Kmethyltransferases
MLL-fusion enriched target genes play a role in HSC function,
MLL mediated activation of HOX genes has been described,
MLL fusions are potent inducers of leukaemia.
[29–32]
SETDB1 H3K9 methyltransferase Essential for HSC function. [33]
PMRT4/5 Protein argininemethyltransferases
PMRT4 blocks myeloid differentiation. PMRT5 inhibits
expression of differentiation associated genes, PMRT5 deletion
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Overexpression increases HSC self-renewal. [45–47]
Ring1B E3 ubiquitin-proteinligase. Antiproliferative role in progenitor expansion. [48]
BMI1/MEL-18 Polycomb ring fingerprotein, PRC1 member.
Repression impairs self-renewal. Frequently overexpressed in
malignant haematopoiesis. Loss enhances HSC self-renewal. [49–52]
LSD1 H3K4/9 demethylase
Overexpression of the short isoform increases self-renewal
potential. Loss causes defects in long-term HSC self-renewal
and impaired differentiation.
[53–55]
JARID1b H3K4 demethylase Described as a positive regulator of HSC self-renewal capacity. [56,57]
KDM6A/UTX H3K27 demethylase
Knock out leads to myelodysplasia, suppressed
megakaryocytopoiesis and extramedullary haematopoiesis,
indicating a regulatory role in haematopoiesis.
[58,59]
KDM6B/JMJD3 H3K27 demethylase Loss impairs HSC self-renewal potential followingproliferative stress. [59,60]
MYSM1 Histone H2Adeubiquitinase
Maintenance of HSC function. Deletion results in impaired
self-renewal. [61–63]
SIRT1/2/3/7 NAD-dependentdeacetylases
Sirt1 loss increases HSC numbers. Sirt2 and 3 are not required
for HSC maintenance at young age, but knockout does
compromise HSC function at old age. Sirt6-deficient HSCs
exhibited impaired self-renewal ability. Sirt7 overexpression
increases constitutive capacity of HSCs.
[64–68]
2. Epigenetic Changes during Normal Aging of Murine HSCs
Genome-wide changes of epigenetic modifications are not only observed upon differentiation,
but have also been identified during normal HSC aging. Studies in mice have shown that aged HSCs
have low self-renewal potential [69–73], which appears to be inversely related to the number of cell
divisions a HSC has undergone [74]. Importantly, the functional capacity of individual murine HSCs is
highly variable and this variation increases during aging. Whereas the large majority of aged HSCs
performs worse than their young counterparts, there are also aged HSC that function just fine [72,75,76].
This massive cell-to-cell variability is unlikely to result from the accumulation of random genetic
mutations, as HSCs divide only very rarely during the lifespan of an organism [77]. Instead, functional
heterogeneity is easier explained by random alterations of epigenetic modifications that may occur
with each cell division.
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Indeed, the functional heterogeneity and limited overlap of differentially expressed genes upon
aging of murine HSCs supports the idea that deterioration of HSC functioning during aging may be
caused by cumulative and random epigenetically inherited gene expression changes, rather than by
mutations in specific loci [69,70,78–89],[Lazare et al. 2016(unpublished)]. Although a comprehensive
overview of alterations of epigenetic histone and DNA modifications that are present in aged murine
HSC is lacking, several age-associated epigenetic alterations have been identified. For example, in
old HSCs trimethylation of lysine 4 of histone 3 (H3K4me3) is more widespread, while a gradual
increase of global DNA methylation levels is observed. This is accompanied by a reduction of 5-hmC
in old HSCs compared to young [79,90]. Concordantly, old HSCs have been reported to down-regulate
expression of genes involved in chromatin regulation, such as chromatin remodelling genes (Smarca4,
Smarcb1), histone deacetylases (Hdac 1, 5,6) and DNA methyltransferases (Dnmt3b) [69]. Intriguingly,
chimeric mice produced from induced pluripotent stem (iPS) cells that were derived from aged HSCs
presented with a rejuvenated haematopoietic system, suggesting that it is possible to reprogram aged
HSCs and reverse the aging process [91]. These findings strongly suggest that it is indeed—potentially
reversible—epigenetic changes that causally contribute to HSC aging.
3. Epigenetic Changes during Normal Aging of Human HSCs
Also in the haematopoietic system of humans there are indications that HSC function deteriorates
with age. For example, inferior engraftment is seen when HSCs from older donors are transplanted
compared to young donors [92]. Beyond differences in functionality, changes in the epigenetic
landscape have been observed in aging human HSCs. Several factors are described to be related to
these changes, such as loss of fidelity in copying the epigenetic marks during cell divisions, and genetic
and environmental factors. Collectively, these lead to epigenetic changes by interfering with regulatory
mechanisms [93,94]. The molecular mechanisms and the extent by which these factors contribute to
epigenetic aging is still not completely clear. An example of epigenetic changes observed in both aged
murine and human HSCs is the reduction in 5hmC levels [79,95].
A most striking observation has been the identification of strongly age-dependent differentially
methylated genomic loci in peripheral blood leukocytes of healthy human donors. Indeed, it is
now possible to accurately predict the chronological age of an individual based on the differentially
methylated status of a very small number of loci in a peripheral blood cell sample [96,97]. Interestingly,
this epigenetic age, based on DNA methylation patterns in leukocytes, appears to be cell-intrinsic
and independent of the environment, as it does not change upon allogenic haematopoietic stem
cell transplantation (HSCT) [98,99]. However, another study that investigated DNA methylation
patterns after allogenic HSCT observed that in fact a short period of ‘rejuvenation’ occurs, followed
by accelerated aging as measured by DNA methylation levels [100]. Patient groups, conditions, time
points and follow-up differed between these studies. This epigenetic clock currently includes only
DNA methylation patterns, but may become even more accurate when other age-related epigenetic
changes can be included. It remains unclear to what extent this epigenetic clock reflects a history of cell
proliferation, and whether it is first established in more primitive haematopoietic cell compartments,
including stem cells.
Beyond these age-related epigenetic changes, it has recently become apparent that in otherwise
healthy elderly people a significant number of blood cells is derived from one, or only a few, dominant
stem cell clones. This is referred to as clonal haematopoiesis of indeterminate potential (CHIP, [101]),
or age-related clonal haematopoiesis (ARCH, [102]). Clonal haematopoiesis is characterized by
the dominant presence of HSCs that carry somatic mutations in genes that are likely to drive the
expansion of a genetically identical clone of haematopoietic cells. Large-scale analysis of blood-derived
genetic data from individuals within the Cancer Genomes Atlas who did not display haematological
malignancies showed age-related expansion of a haematopoietic stem- or progenitor cell clone and
the concurrent presence of leukaemia/lymphoma-associated mutations in about 2% of individuals
studied. This frequency increased to 5–6% for individuals who are at least 70 years of age [103].
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These intriguing findings have been confirmed in multiple independent cohorts ([103–105] and many
more). Healthy individuals with clonal haematopoiesis have a significantly higher change to develop
haematological malignancies, or indeed other disease [106,107]. Although our molecular understanding
of the mechanisms that lead to age-related clonal haematopoiesis at present is far from complete, it
is interesting to note that mutations were found in genes encoding for proteins in involved in DNA
(de-)methylation (DNMT3A and TET2) and chromatin compaction (ASXL1).
4. Epigenetic Changes in Age-Related Haematopoietic Malignancies
Mutations in these epigenetic modifiers in individuals who display CHIP or ARCH, are not
only found in normal aging, but are also considered to be critical in the development of acute
myeloid leukaemia (AML) and acute lymphoid leukaemia (ALL) [30]. Presumably, mutations in
the aforementioned genes result in aberrant epigenetic regulation in HSCs, which derail proper
control of HSC self-renewal programs, and thus constitute the initiating events in the pathogenesis
of haematological malignancies. Aberrant epigenetic marks, epi-mutations, are prevalent in many
myeloid leukaemias [18]. In leukaemia, (epigenetic) dysregulation may lead to the accumulation of
immature, non-functioning pre-malignant cells. The malignant transformation subsequently results
from the activation of oncogenes and self-renewal pathways or from silencing of tumour suppressor
genes, repression of differentiation or apoptosis pathways. These molecular events can be induced
by hypermethylation of promotor regions, increased Polycomb repression or aberrant chromatin
conformation [108]. It has been shown in a cohort of 200 cases of de novo AML that 74% of patients had
at least one mutation in an epigenetic modifier [109]. The three most recurrently mutated genes in AML
affecting these aberrant DNA methylation patterns (DNMT3A and TET2) and histone modifications
(ASXL1) will be discussed below.
4.1. Aberrant DNA Methylation
DNA methylation patterns have been used to stratify clinically relevant subgroups among
AML patient samples [18]. Although clustering appeared possible, patterns were complex and not
straightforward to interpret. Whereas ~25% of the differentially methylation clusters corresponded
to known AML subtypes, four epigenetic subtypes were defined among patients who shared NPM1
mutations, some clusters were enriched for specific genetic abnormalities, and novel clusters appeared.
Overall, while in most AML cases DNA hypomethylation was prevalent, there were also subgroups
that showed hypermethylation [18]. Thus, aberrant hyper- as well as hypomethylation states are found
in haematological malignancies.
DNMT3A, encoding for a de novo DNA methyltransferase, is one of the most mutated genes
in AML. For de novo AML almost 20% of the patients carry mutations in this gene [110], while for
de novo MDS this is ~13% [111]. Heterozygous mutations of DNMT3A have been observed to lead
to the development of myeloid leukaemias, implying that DNMT3A qualifies as a haploinsufficient
tumour suppressor gene [110,112–114]. DNMT3A mutations have been associated with poor prognosis
(reviewed in [114]), however not in all studies [112]. Functional studies show that loss of the de
novo methyltransferase DNMT3A increases HSC self-renewal in mice [8–10]. Correspondingly, most
DNMT3A mutations are loss of function mutations and the most common DNMT3A mutation is
associated with hypomethylation, although hypermethylated regions have also been found [115–117].
TET2 is another frequently mutated gene in haematopoietic malignancies. TET2 encodes a
protein that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine and constitutes
the first step towards DNA demethylation. Loss-of-function mutations and deletions of Tet2 have been
associated with DNA hypermethylation [118]. Loss of TET2 increased HSC self-renewal in functional
studies in murine HSCs [13,18]. Restoration of TET2 function blocked aberrant self-renewal and
leukaemia progression in chimeric mouse models [119]. TET2 mutations are detected in 7–23% of AML
cases, 10–20% of MDS cases [120] and 50% of chronic myelomonocytic leukaemia (CMML) cases [121].
In de novo AML with TET2 mutations hypermethylated promotor regions were found, overlapping
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with IDH1/2 mutated leukaemias [14]. TET2 mutations are associated with an increased risk of MDS
progression and confer a poor prognosis in AML [13,119]. Low TET2 mRNA levels are related to poor
prognosis and TET2 mRNA levels might be a potential prognostic biomarker for AML since levels
increase upon remission and decrease upon relapse [122].
4.2. Aberrant Histone Modifications
In addition to changes at the DNA level described earlier, multiple modifications of
post-translational histone modifications have been found in haematological malignancies [123]. These
aberrant modifications in leukaemia are diverse and often include altered methylation states of histone
H3, mainly at lysine residues K4, K9, K27, K36 and K79 [124,125]. Perturbed histone modifications
are presumably caused by altered expression of histone modifying enzymes. Indeed, high expression
levels of histone deacetylases (HDAC) are found in several types of cancer [126]. In myeloid leukaemias
the expression levels of HDACs are heterogenous, where HDAC levels were generally increased
in CLL [127]. Also, overexpression of histone demethylases, such as LSD1 has been observed in
leukaemia [128]. In addition, genes involved in histone methylation and demethylation, for example
ASXL1, EZH2, and DOT1L are frequently mutated in myeloid malignancies.
ASXL1 is associated with the repressive H3K27me3 mark and is one of the three most commonly
mutated epigenetic modifiers genes in AML. ASXL1 mutations were found to confer a global reduction
of H3K27 trimethylation by disrupting normal recruitment of PRC2 [40]. Loss of Asxl1 was reported to
lead to MDS-like disease in mice [41], whereas enforced overexpression of truncated forms of ASXL1
show gain-of-function and promote the pathogenesis of myeloid malignancies [129,130]. Acquired
somatic mutations in ASXL1 occur in approximately 10–20% of patients with MDS and 15–25% in
myeloproliferative neoplasms (MPN) and AML [131–134]. Mutations in ASXL1 are associated with
poor prognosis in malignant myeloid diseases [131,135].
Beyond mutations in epigenetic histone modifiers, mutations affecting lysine residues in histone
H3 genes have also been described. These have an inhibitory effect on EZH1/2, thereby causing
reductions in H2K27me2/3. These mutations have a high prevalence in paediatric glioblastoma, but
were recently also characterized in adult AML representing sporadic mutations and may co-occur with
RUNX1 aberrations [136].
Although these studies clearly suggest a role for aberrant histone modifications in the aetiology of
leukaemia, it is difficult to draw definitive conclusions as to how exactly each modification contributes
to disease progression. Histone methylation can repress or activate gene expression, depending on
which lysine is methylated. For definitive molecular insight it would be required to obtain single cell,
single locus and single molecule resolution of histone modifications, and current technology does not
permit such approaches. Additionally, discerning between levels of active and repressive marks is
complicated by the fact that leukaemic mutations in methyltransferases that deposit active marks,
such as the H3K4 and H3K36 methyltransferases, are both gain and loss of function, respectively [125].
Most mutations in genes encoding PRC2 proteins, involved in deposition of the repressive H3K27me3
mark, such as SUZ12, EED and EZH2, , are loss of function mutations. In contrast, mutations in
genes encoding for proteins involved in the deposition of other repressive marks, such as H3K9me1
methyltransferases, turn out to be gain of function mutations [125]. Similar as the DNA hypo- and
hypermethylated states that are found in AML (as described above), both gain and loss of H3K27me3
levels seems to promote malignant transformation. Similarly, both overexpression and loss of EZH2 are
associated with malignant transformation [23,137]. Loss-of-function mutations have been described
in CMML and in AML [137–139], whereas gain-of-function mutations are frequently encountered in
lymphoma patients [140], but also in chronic myeloid leukaemia (CML) and lymphoid leukaemias [137].
In case of MDS and T-ALL, both overexpression and inactivating mutations have been described [137],
indicating aberrant expression in either way may drive oncogenesis. It is conceivable therefore that any
perturbation of the stochiometry of epigenetic writers, readers and erasers in large protein complexes
may cause primitive haematopoietic cells to proliferate uncontrollably and, thus, results in malignancy.
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5. Epigenome-Targeted Therapies
The presence of epigenetic modifications in leukaemia and the potential reversible nature of many
epigenetic modifications suggest that compounds that affect the epigenetic machinery may be used for
therapeutic purposes. Indeed, multiple pharmacological intervention strategies to reverse potentially
pathological epigenetic modifications are in development (Table 2). DNA methyltransferase inhibitors
(DNMTi) were the first FDA approved drugs targeting the epigenome, aimed to treat haematological
diseases, such as MDS, AML and CMML [141]. In addition to drugs that affect DNA methylation, the
clinical potential of compounds that target proteins involved in histone modifications is also actively
explored. The first histone deacetylase inhibitors (HDACi), approved for multiple myeloma and
cutaneous T cell lymphoma, are in clinical trials [142]. Histone methyltransferase inhibitors (HMTi) and
histone demethylase inhibitors (HDMi) are emerging as strategies in epigenetic-based pharmacology.
Small-molecule inhibitors of histone acetyltransferase (HATi) are investigated in pre-clinical studies.
These approved DNMTi and HDACi, initially used for the treatment of haematological malignancies,
are currently also being tested in clinical trials for other diseases, such as neurological diseases, latent
viral infections and immune diseases [143].
5.1. DNA Methylation Inhibitors (DNMTi)
DNMTi are nucleoside analogues that form a covalent complex with DNA methyltransferases
(DNMT) and thereby inhibit ongoing methylation. After their incorporation into DNA, these inhibitors
sequester DNMT enzymes, leading to gradual and global demethylation upon cell division. The two
most commonly used DNA methylation inhibitors, azacitidine and decitabine, have been evaluated
in several clinical trials and are incorporated in clinical guidelines [141]. Azacitidine is approved
for MDS and AML and provides an increase in overall survival in older AML patients with poor
prognostic karyotypes and high risk MDS (AZA001 trial) [144]. However, it is important to note
that only half of the treated patients show a response to azacitidine treatment. Criteria to stratify
patients who will respond to these drugs have not yet been identified [145]. Overall survival of MDS
patients in the AZA001 trial was superior to survival in cohorts of patients treated in normal clinical
practice outside of clinical trials, discouraging routine treatment with azacitidine above enrolment
in clinical trials [146]. Survival rates of patients with AML and MDS with cytogenetic abnormalities
associated with unfavourable risk, with TP53 mutations, or with both, were similar to patients with
an intermediate-risk cytogenetic profile after decitabine treatment [147]. This suggests a place for
decitabine in treating these patients. In addition, these DNA hypomethylating agents were reported to
have higher overall response rates in MDS and AML patients with TET2 mutations, associated with
DNA hypermethylation [118]. Counterintuitively, hypomethylating agents also appear effective in
DNMT3A mutated AML, which is associated with hypomethylation, and a small study suggests patients
might respond even better [148]. These hypomethylating agents may target specific hypermethylated
regions or may result in even further hypomethylation of the genome [114].
The disadvantage of DNMTi is that they induce genome-wide hypomethylation and lack locus
specificity, which could lead to activation of oncogenes and/or increased genomic instability. Further
research into the long term effects of treatment with DNMTi might learn us more about the therapy
related effects and whether the association with therapy related malignancies is comparable to that
of commonly used chemotherapeutics. Considering the heterogeneity of AML as a disease, the
effectiveness of DNMTi will likely depend on the leukaemia subtype and is likely to vary from patient
to patient. Insight into the molecular mechanism of aberrant DNA methylation patterns and the
following development of criteria for responders can lead the way to use of these drugs for the
right subgroups of AML patients. It is relevant to note that upon azanucleoside withdrawal DNA
methylation levels return to pre-treatment levels [149]: demonstrating a continuous need for DNA
methyltransferase inhibition.
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5.2. Histone Deacetylase Inhibitors (HDACi) and Histone Acetyltransferase (HATi)
Histone acetylation is an epigenetic mark that is typically associated with active gene expression.
Concordantly, inhibition of histone deacetylases by HDACi has been shown to derepress expression of
genes involved in cell death, growth arrest and differentiation in myeloid malignancies [142,150–153].
The mechanism of action of most HDACi is by binding to the catalytic site of the HDAC enzyme. HDACi
can also affect acetylation of non-histone proteins potentially leading to more general effects [125],
including the inhibition of DNA repair processes [154]. For example, DNA damage can be induced by
the HDACi vorinostat, possibly by creating a more susceptible, open chromatin conformation. There
are reports that suggest that HDACi-induced DNA damage can be repaired by normal cells but not by
malignant cells [153]. Treatment of AML or MDS patients with HDACi only, showed low response
rates in 10–20% [155].
The use of different combinations of drugs with HDACi is currently being explored. Cameron et al.
have addressed the rationale for such combination, e.g., HDACi and DNMTi already in 1999 [156].
An approved HDACi combination is panobinostat combined with bortezomib and dexamethasone for
treatment of multiple myeloma (FDA and EMA approved in 2015) [157]. Sequential administration of
DNMTi and HDACi demonstrated clinical efficacy in patients with haematologic malignancies [158].
Additionally, pracinostat (SB939) combined with azacitidine is tested for efficacy and safety in a phase
III AML trial (NCT03151408) [143]. Beyond inhibition of histone deacetylases, inhibition of histone
acetyltransferases has also been evaluated [159]. This includes inhibition of p300 with small molecules
to induce apoptosis in AML cells in pre-clinical setting [160].
5.3. Histone Methyltransferase Inhibitors (HMTi) and Histone Demethylase Inhibitors (HDMi)
Disruption of histone methylation patterns is another potential therapeutic strategy to (de)repress
differentiation-inducing genes in cancer. The histone methyltransferase inhibitor tazemetostat, an EZH2
inhibitor, is tested for relapsed or refractory B cell NHL with EZH2 mutations [161,162]. Inhibitors
targeting histone demethylases, such as the lysine specific demethylase (LSD1) inhibitor, INCB059872,
are evaluated in phase I/II clinical MDS/AML trials [143].
Table 2. Examples of epigenetic drugs and their stage of development for treatment of
haematological malignancies.
Type of Drug Target Enzyme Compound Stage of Development References
DNMTi DNAmethyltransferase Azacitidine, decitabine
EMA and FDA approval for
MDS, AML and CMML [163]
IDH1/2 inhibitors Pre-clinical and clinical
[164–166]
Ivosidenib (IDH1) EMA and FDA approval forIDH1 mutated and R/R AML
Enasidenib (IDH2) EMA and FDA approval forR/R AML
HDACi Histonedeacetylases Panobinostat
EMA and FDA approval for
MM, CTCL [125,142,152,154]
Romidepsin EMA and FDA approval forCTCL
HATi Histoneacetyltransferases P300 inhibitors Pre-clinical [159,160,167]
HDMi Histonedemethylases LSD1 inhibitors Pre-clinical and clinical [128,168]
HMTi Histonemethyltransferases
EZH1/2 inhibitors
Tazemetostat (EZH2) Pre-clinical and clinical [169,170]
DOT1L inhibitors Pre-clinical and clinical [128,171]
MENIN1-MLL
interaction inhibitors Pre-clinical [128]
HATi Histone acetylreaders BET-inhibitors Pre-clinical and clinical [163,166]
(myelodysplastic syndrome (MDS), relapsed/refractory (R/R) acute myeloid leukaemia (AML), chronic
myelomonocytic leukaemia (CMML), multiple myeloma (MM), cutaneous T cell lymphoma (CTCL))
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5.4. Inhibiting Epigenetic Readers
Broadly acting epigenetic drugs will lead to genome wide alterations of epigenetic modifications.
DNMTi, for example, have genome-wide effects on the DNA methylome, leading to acute genome-wide
DNA demethylation of repetitive elements, as well as loss of methylation of specific tumour suppressor
genes and normalization of cell growth [143]. To reduce these genome wide effects and associated
side effects, more specific epigenetic targeting therapies are investigated in preclinical settings. Small
molecules that specifically target the binding of epigenetic modifier proteins may be of use for this.
The development of BET inhibitors, that preferentially prevent binding of bromodomain-containing
epigenetic reader proteins to acetylated histones and transcription factors, served as a proof of
principle that there are epigenetic drugs which are able to inhibit certain protein interactions more
specifically [123,172]. Development of epigenetic drugs directed against specific protein-protein
interactions and thereby influencing epigenetic regulation is ongoing, including compounds that
prevent binding of PRC1/2 complexes (EZH2—[162], CBX7—[47,173–175]).
6. Future Prospects
It is important to remember that our knowledge of molecular mechanisms that contribute to HSC
aging is essentially based on studies in mice, whereas the clinical implications (anaemia, increased
susceptibility to infections and malignancies) are evident in human studies. We assume that the
clinical observations made in human patients result from the molecular changes that have been well
documented in mice, but at this point this remains to be proven. To cover this gap in knowledge, more
insight in human HSC aging and robust mouse aging models are required. This also relates to the
concept of age-related clonal haematopoiesis, which is very well described in humans, but much less
in mice.
As less than one percent of elderly people with clonal haematopoiesis develop leukaemia,
identification of those who will eventually develop haematological malignancies is of great interest.
Once these individuals can be accurately identified it may be possible to prevent development of
leukaemia by specifically targeting the emerging preleukaemic clones in elderly people. For reasons
that we do not understand, elderly people with age-related clonal haematopoiesis also have increased
risk to present with a wide variety of non-haematological conditions [106,107]. It is tempting to
speculate that eradicating aberrant haematopoietic stem cell clones may also be beneficial to prevent
these non-haematological diseases.
Once persistent and systematic epigenetic changes have been identified, the plasticity of such
lesions renders them an interesting target for novel therapeutic strategies. Epigenetic therapy in AML
is in development, many new targets and inhibitors are being explored. The first epigenetic compounds
are already approved for clinical use in haematopoietic malignancies and more specific epigenetic
therapies are in development and are studied in (pre)clinical studies. Finding ways to specifically
target the aberrant epigenetic marks in abnormal HSCs while sparing healthy HSCs would potentially
be of significant clinical interest. These newly developed epigenetic drugs may be beneficial as single
agent, but also in combinations with commonly used chemotherapeutics, immune therapy or other
epigenetic drugs [176]. Reactivation of epigenetically silenced apoptotic genes may increase efficacy
of chemotherapy.
Unfortunately, development of new drugs for AML is impeded by the heterogeneity of this disease.
The resulting variability in response rates warrants the need for disease stratification and biomarkers
to discern which patients will benefit from new treatments. Epigenetic aberrations and mutations in
epigenetic modifiers may be useful in this context [177–179]. Beyond patient stratification, epigenetic
alterations may play a role in prognostic evaluations since mutations in several epigenetic modifiers
are associated with clinical outcome in patients with malignant diseases (for example DNMT3A, TET2,
IDH2, MLL, EZH2 and ASXL1; reviewed in [123]).
Upon aging many changes in the epigenetic landscape of HSCs occur, both in the murine and the
human haematopoietic system. However, the functional consequences of these epigenetic perturbations,
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although likely to be relevant, remain unclear at this point. Elucidating the functional role of epigenetic
modifications that occur during aging and during malignant transformation is partially provided by
large-scale analysis of epigenetic modifications in patients with haematological disease (such as the
BLUEPRINT project, part of The International Human Epigenome Consortium) [180]. Such important
descriptive studies must be followed by functional studies unravelling how epigenetic changes are
regulated and lead to aberrant gene expression and phenotypes.
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